Apollon Formularies PLC - London-based medical cannabis pharmaceutical firm - Advancing application to join OTCQB Market in US. Says shares will continue to trade on Aquis Stock Exchange. "The company decided to undertake this application for a second trading platform for its shares at the request of several US based investors and believes that cross trading on the OTCQB will provide enhanced investor benefits, including easier access for potential investors in North America, increased trading hours and improved trading liquidity,"
Apollon says. Company adds it is also exploring "other possible up-listing options", including local and international exchanges. "The company will maintain its existing AQSE listing, in addition to any additional up-listing it may undertake," Apollon adds.
Current stock price: 2.5 pence
12-month change: down 64%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.



